Evidence map›Paper›PMID 33868165›Full record

ArticleFrontiers in endocrinology2021

Testicular Growth and Pubertal Onset in GH-Deficient Children Treated With Growth Hormone: A Retrospective Study.

Rossella Cannarella, Manuela Caruso, Andrea Crafa, Tiziana Antonia Timpanaro, Manuela Lo Bianco, Santiago Presti, Rosita A Condorelli, Sandro La Vignera, Aldo E Calogero

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Rossella CannarellaEndocrinology, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Manuela CarusoPediatric Endocrinology, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Andrea CrafaEndocrinology, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Tiziana Antonia TimpanaroPediatric Endocrinology, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Manuela Lo BiancoPediatric Endocrinology, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Santiago PrestiPediatric Endocrinology, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Rosita A CondorelliEndocrinology, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Sandro La VigneraEndocrinology, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
Aldo E CalogeroEndocrinology, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
University of Catania · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prevalence of idiopathic oligozoospermia has been esteemed as high as 75%. An Italian survey has reported bilateral testicular hypotrophy in 14% of final-year high school students. The search for determinants of testicular growth in childhood is important for the primary prevention of spermatogenic failure. Therefore, this retrospective study aimed to evaluate the testicular growth and pubertal onset in deficient children treated recombinant human growth hormone (rhGH). To accomplish this, the clinical charts of 93 patients with GH deficiency (GHD) were carefully reviewed. Their mean age at the time of diagnosis was 11.2 ± 2.4 years. rhGH was administered for 44.0 ± 22.4 months, and the onset of puberty was recorded after a mean of 25.8 ± 22.4 months from the first rhGH administration. As expected, serum insulin-like growth factor 1 (IGF1) levels increased significantly after treatment. Before rhGH therapy, the Tanner stage was I in 59 out of 70 boys (84.3%), II in 8/70 (11.4%), III in 3/70 (4.3%). No one was on stage IV or V. The mean Tanner stage was 1.19 ± 0.51. At the last visit, the Tanner stage was I in 8/72 boys (11.1%), II in 6/72 (8.3%), III in 6/72 (8.3%), IV in 16/72 (22.2%), and V in 36/72 (50.0%). After a mean of 44.0 ± 22.4 months of rhGH treatment, the mean Tanner stage was 4.05 ± 1.30. Patients treated with rhGH showed a significant testicular volume (TV) growth over time, whereas no growth was observed in age-matched but not yet treated patients, even when the age was compatible with a spontaneous start of puberty. The multivariate regression analysis showed that the duration of treatment and the mean rhGH dose significantly predicted the percentage of TV increase. In contrast, age, serum FSH, and IGF1 levels, and final rhGH dose did not impact TV growth over time. In conclusion, these findings suggest that GH may play a role in testicular growth and pubertal onset, despite the descriptive nature of this study. Further properly designed studies are needed to confirm these findings. This knowledge may be useful to implement the diagnostic-therapeutic algorithm in case of a lack of testicular growth in childhood.

Indexed as

Hormone Replacement TherapyAdolescentChildGrowth DisordersHuman Growth HormoneHumansInsulin-Like Growth Factor IMalePubertyRecombinant ProteinsRetrospective StudiesTestisHuman Growth HormoneIGF1 protein, humanInsulin-Like Growth Factor IRecombinant ProteinsGHDGH deficiencyIGF1infertilityoligozoospermiatesticular growthtesticular volume

Identifiers

PMID33868165
PMCPMC8050347
OpenAlexW3143403219

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.